CT-868-004 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants with Type 1 Diabetes Mellitus

Study Purpose: To evaluate the safety and tolerability of the study drug, CT-868, and to study the effect that CT-868 has on Type 1 Diabetes and weight.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria:

Study Duration: 25 Weeks

Age: 18+ years old

Sex: Male & Female

Conditions/Eligibility: Male or Female, 18+ years of age.
Diagnosed with Type 1 Diabetes for at least 1 year.
BMI of 27 or higher.
Currently receiving insulin treatment.
Must be wearing a CGM.
Must be a non-smoker.

Study Procedures: 1 Screening visit: informed consent, vitals, blood draw, medication and medical history review, physical exam, pregnancy test, urinalysis and urine drug screen, 12-lead ECG
12 outpatient visits at the study site
8 phone calls

Compensation: Up to $2150.00